fusion technology is widely used in protein-drug development to increase activity, stability, and bioavailability of protein therapeutics. fusion proteins, like any other type of biopharmaceuticals, need to remain stable during production and storage. Due to the high complexity and additional intramolecular interactions, it is not possible to predict the behavior of fusion proteins based on the behavior the individual proteins. therefore, understanding the stability of fusion proteins on the molecular level is crucial for the development of biopharmaceuticals. the current study on the albuminneprilysin (HSA-nep) fusion protein uses a combination of thermal and chemical unfolding with small angle X-ray scattering and molecular dynamics simulations to show a correlation between decreasing stability and increasing repulsive interactions, which is unusual for most biopharmaceuticals. it is also seen that HSA-NEP is not fully flexible: it is present in both compact and extended conformations. Additionally, the volume fraction of each conformation changes with pH. finally, the presence of nacl and arginine increases stability at pH 6.5, but decreases stability at pH 5.0.